Tezepelumab-Ekko

Biologic
Prescription only
Identity checked
Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

TEZSPIRE is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated: • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

Tezepelumab-ekko is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody IgG2λ that binds to human TSLP with a dissociation constant of 15.8 pM and blocks its interaction with the heterodimeric TSLP receptor. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in inflammatory cascades. Airway and mucosal inflammation are important components of the pathogenesis of asthma and CRSwNP. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes, ILC2 cells) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in airway and mucosal inflammation.

Why people take it. TEZSPIRE is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated: • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts: Not recorded.
Kind of result: No result is published, so no kind of result applies yet
Supervision: RNAWiki has not recorded a supervision or regulatory status for this substance.

What the registries record it as

The substance registry classes this as protein.
FDA substance registry · RJ1IW3B4QX · read 2026-08-29

Where each sentence above came from

The use the label states, quoted from it. No plain-language version of this sentence has been written.

The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.

No statement of the main limit is recorded.

The four opening statements run to 166 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Formulation

A formulation is the exact made-up form a substance comes in.

A picture of it, and where the picture fails

It is like the difference between a whole bean and instant coffee.

Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.

What people get wrong. Two products with the same name are assumed to behave the same. They often do not.

The specific composition and physical form of a product, including salt, excipients and release profile.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Total Nasal Symptom Score (TNSS)

The study did not show it

Who was studied: NCT06189742
How many people: 19
Study design: Phase 2
Compared against: Not recorded for this study
Kind of result: A number that stands in for health
What was found: Result not recorded on this page
Repeated elsewhere: Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

openFDA Drugs@FDA · a recorded source, not a stored snapshot
FDA nonproprietary naming guidance for biological products · a recorded source, not a stored snapshot

What we know: RNAWiki holds 1 written-up human studies for this substance, each with the question it asked.
How we know it: Each card names the study, the number of people and what the study set out to measure.
What this does not prove: These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters: A study that failed is as informative as one that worked, and both are here.
What we still do not know: No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

Acute bronchospasm or status asthmaticus

Who is missing from the studies

Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

On pediatric, the label states: “The safety and effectiveness of TEZSPIRE have not been established in patients younger than 12 years of age with asthma.”
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-30
On older people, the label states: “Asthma Of the 665 patients with asthma treated with TEZSPIRE in clinical trials (PATHWAY and NAVIGATOR) for severe asthma, 119 patients (18%) were 65 years or older.”
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of tezepelumab-ekko in human milk, its effects on the breastfed infant, or its effects on milk production.”
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-30

Where the result stopped carrying

This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

A different form was studied

The studied form is not the form on the shelf.

On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (10)

It was studied for a different goal: The studies measured something else entirely. Nothing in this record points to this reason.
There was nothing to correct: Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too: In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel: A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it: Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet: The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied: Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time: Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says: Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason: RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No form or route is recorded.

No source is stored against this line.

Who oversees it

RNAWiki has not recorded a supervision or regulatory status for this substance.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

No register row and no identity class settled the question.

No source is stored against this line.

What is in the pack

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing is recorded about product quality.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

The exact form studied is not recorded.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-29
TEZSPIRE is subcutaneous at 3 DOSAGE FORMS AND STRENGTHS Injection: a clear to opalescent, colorless to light yellow solution available as: • 210 mg/1.91 mL (110 mg/mL) solution in a single-dose glass vial. • 210 mg/1.91 mL (110 mg/mL) solution in…, recorded as fda label in effect 2025-10-17 in the United States.
US prescribing information · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · read 2026-08-30

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

Names and forms linked to this record

Biosimilar of
Tezepelumab
Evidence on this page does not automatically apply to this one.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.

Questions worth asking

Which of the trials of Tezepelumab-Ekko studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Tezepelumab-Ekko are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

Where else this substance is registered

FDA substance identifier (UNII): RJ1IW3B4QX
RxNorm concept: 2587794

Checks this page had to pass

Passed
Identity resolved
no open identity hold
Passed
No unresolved merge across substance families
no quarantine open
Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
Not passed
Safety mode resolved
No register row and no identity class settled the question.
Passed
Canonical metadata present
slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

1 approved application covers products containing this substance. The earliest was BLA761224, approved 20211217 to ASTRAZENECA AB.
Drugs@FDA application register · BLA761224 · read 2026-08-29
Marketing status on the register: prescription.
Drugs@FDA application register · BLA761224 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

Which studies of this failed, and what did they measure?Surface a meaningful outcome
Were people like me actually studied?Reveal a population mismatch
How close is this evidence to something I would notice?Reveal the evidence boundary
What does nobody know about this yet?Reveal an important unknown
What is a formulation?Support deeper learning

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (6)

On the Tezepelumab-Ekko label: indicated for what?

"TEZSPIRE is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated: • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. ( 1.1 ) Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus.": indications and usage on Tezepelumab-Ekko's label. DailyMed label · 60f0aa03-ad25-4d48-80ce-7fcfa76f325f · 2025-10-17

17 registered trials of Tezepelumab-Ekko — at which phases?

Registered studies posting no result: 9 of 17

17 registered studies of Tezepelumab-Ekko: 7 phase1, 5 phase2, 4 phase3, 2 na or unstated. CLINICALTRIALS_SNAPSHOT · 2026-09-01

0 with a PubMed record

Show the evidence

phase1
7
phase2
5
phase3
4
na or unstated
2
completed
10
not yet recruiting
3

2 more recorded rows

active not recruiting
2
recruiting
2

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Tezepelumab-Ekko used MEDI9929 70 mg — over how long?

Human studies of Tezepelumab-Ekko used "MEDI9929 70 mg". ClinicalTrials.gov · 2026-09-01

4 recorded entries; human; also "MEDI9929 210 mg", "MEDI9929 280 mg", "MEDI9929, 140 mg"

Show the evidence

human

NCT02054130
MEDI9929 70 mg
NCT02054130
MEDI9929 210 mg
NCT02054130
MEDI9929 280 mg
NCT02512900
MEDI9929, 140 mg

recorded 2026-09-01 · last checked 2026-09-04